Sanofi to Acquire US Biotech Dynavax for $2.2 Billion
Reuters
7 hours ago
Dec 24 (Reuters) - French drugmaker Sanofi has entered into an agreement to acquire U.S. vaccines company Dynavax Technologies Corporation for around $2.2 billion (1.87 billion euros), it said on Wednesday.
Under the terms disclosed, Sanofi will pay $15.50 per share in cash, representing a 39% premium over Dynavax's Tuesday closing price and a 46% premium over its three-month volume-weighted average price.
Dynavax shares jumped 7.8% in overnight trading.
Sanofi expects to complete the acquisition in the first quarter of 2026 and says it will use available cash. The deal will not affect its 2025 financial outlook, it adds.
(1 euro = $1.1789)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.